Gelsomino, Francesco
Tiseo, Marcello http://orcid.org/0000-0002-9204-1728
Barbieri, Fausto
Riccardi, Ferdinando
Cavanna, Luigi
Frassoldati, Antonio
Delmonte, Angelo
Longo, Lucia
Dazzi, Claudio
Cinieri, Saverio
Colantonio, Ida
Sperandi, Francesca
Lamberti, Giuseppe
Brocchi, Stefano
Tofani, Lorenzo
Boni, Luca
Ardizzoni, Andrea
Article History
Received: 16 July 2019
Revised: 14 March 2020
Accepted: 1 April 2020
First Online: 29 April 2020
Change Date: 19 May 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41416-021-01439-1
Ethics approval and consent to participate
: The study protocol was approved by each local institutional ethics committee (a list of the Ethics Committees that approved the study is available in S.InternalRef removed, InternalRef removed) and conducted in accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice and the Declaration of Helsinki. Written informed consent was obtained from all participants.
: No individually identifiable data is presented.
: Anonymised dataset may be available from the corresponding author on reasonable request.
: A.A. has received research grant support from BMS and Celgene; personal fees for serving in a consultant and/or advisory role for BMS, MSD and Boehringer; honoraria from Eli-Lilly and Pfizer. A.F. has received personal fees for serving in a consultant and/or advisory role for Novartis, Roche and Astrazeneca; honoraria from Novartis, Astrazeneca, Pfizer, Lilly, Eisai, Roche, Novartis and Celgene. L.C. has received personal fees for serving in a consultant and/or advisory role for Astrazeneca and Merck; honoraria from Celgene, Pfizer and Ipsen. The remaining authors declare no competing interests.
: The study was sponsored by Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) and partially supported by Celgene that provided investigational medicinal product and a restricted grant for the management of study procedures.